Alberto Catalano

Sydney, NSW, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Advancing diagnostic targeted RNA sequencing for haematological malignancies within an Australian sample exchange program.

Advancing diagnostic targeted RNA sequencing for haematological malignancies within an Australian sample exchange program.

Journal: Pathology

Published: March 23, 2025

FLT3-TKD Measurable Residual Disease Detection Using Droplet Digital PCR and Clinical Applications in Acute Myeloid Leukemia.

FLT3-TKD Measurable Residual Disease Detection Using Droplet Digital PCR and Clinical Applications in Acute Myeloid Leukemia.

Journal: International journal of molecular sciences

Published: March 28, 2024

Sensitive monitoring of acute promyelocytic leukemia by PML-RARA DNA Q-PCR.

Sensitive monitoring of acute promyelocytic leukemia by PML-RARA DNA Q-PCR.

Journal: Leukemia & lymphoma

Published: December 01, 2016

Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.

Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.

Journal: The Lancet. Haematology

Published: April 21, 2015

Using digital polymerase chain reaction to detect minimal residual disease in myeloma by identifying FGFR3 up-regulation.

Using digital polymerase chain reaction to detect minimal residual disease in myeloma by identifying FGFR3 up-regulation.

Journal: Leukemia & lymphoma

Published: February 05, 2015

All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).

All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).

Journal: Blood

Published: June 21, 2012

Hyperpigmentation of the hard palate associated with imatinib therapy for chronic myeloid leukemia with a genetic variation in the proto-oncogene c-KIT.

Hyperpigmentation of the hard palate associated with imatinib therapy for chronic myeloid leukemia with a genetic variation in the proto-oncogene c-KIT.

Journal: Leukemia & lymphoma

Published: June 21, 2012

Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia.

Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia.

Journal: Haematologica

Published: October 14, 2011

Showing 1-8 of 8

Last Updated: 09/26/2026